Finance

Vitex Files Shelf Registration Statement

Published in AIDS Weekly, June 13th, 2005

V.I. Technologies, Inc. (VITX), a biotechnology company developing anti-infective products, announced that it has filed a shelf registration on form S-3 with the U.S. Securities and Exchange Commission (SEC).

The filing, when declared effective by the SEC, will allow Vitex, from time to time to offer and sell up to $50 million of equity securities. The terms of any offering made pursuant to this filing will be established at the time of the offering.

The company intends to use the proceeds from the sale of any securities to fund its internal discovery and development programs including the clinical development of its HIV therapeutic drug candidate...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2005-06-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry